Mayumi Funagayama
Overview
Explore the profile of Mayumi Funagayama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Komaki K, Funagayama M, Saitoh T, Maeda Y, Hayashi T, Kanematsu M, et al.
J Med Invest
. 2020 Nov;
67(3.4):368-371.
PMID: 33148919
Mammary hamartoma is benign lesion and relatively rare. 17 cases of breast cancer associated with a hamartoma had been previously documented in the literature. We describe herein a case of...
2.
Maeda Y, Funagayama M, Shinohara A, Koshimoto C, Furusawa H, Nakahara H, et al.
J Physiol Biochem
. 2014 Aug;
70(3):849-55.
PMID: 25108556
The influence of human serum albumin (HSA) on the bile acid-mediated inhibition of liver microsomal type 1 11β-hydroxysteroid dehydrogenase (11β-HSD1) was studied in vitro. A rat liver microsomal fraction was...
3.
Miike T, Yamamoto S, Tahara Y, Hasuike S, Funagayama M, Maehara N, et al.
Nihon Shokakibyo Gakkai Zasshi
. 2014 Jul;
111(7):1376-83.
PMID: 24998728
A 49-year-old woman visited a local hospital in October 2007 with complaint of fever and melena. Abdominal ultrasonography and abdominal computed tomography revealed an irregular mass in the lower abdomen,...
4.
Nakahara H, Yasuda Y, Machida E, Maeda Y, Furusawa H, Komaki K, et al.
Breast Cancer
. 2010 Nov;
18(3):152-60.
PMID: 21086082
Background: Neoadjuvant chemotherapy (NAC) is commonly utilized to treat operable breast cancer. The purpose of this study was to review the findings of ultrasonography (US) and magnetic resonance (MR) imaging...
5.
Funagayama M, Kondo K, Chijiiwa K, Kataoka H
World J Surg
. 2010 Mar;
34(7):1563-71.
PMID: 20213201
Background: Hepatocyte growth factor activator inhibitor type 1 (HAI-1), one of the Kunitz-type serine protease inhibitors, has an important role in cancer progression through regulation of the activity of hepatocyte...
6.
Kondo K, Chijiiwa K, Funagayama M, Kai M, Otani K, Ohuchida J
World J Surg
. 2008 Jul;
32(10):2223-9.
PMID: 18642042
Background: Hepatic resection is one of the main treatment modalities for patients with hepatocellular carcinoma (HCC); however, surgery is generally stressful and often is avoided for elderly patients. This retrospective...
7.
Maehara N, Chijiiwa K, Eto T, Funagayama M, Uchiyama S, Nakashima S, et al.
Hepatogastroenterology
. 2008 Jul;
55(82-83):512-6.
PMID: 18613398
Background/aims: Gastrointestinal stromal tumor (GIST) is recently defined as a tumor expressing c-kit and sometimes showing liver metastasis. We investigated the outcomes of gastric GIST with special attention to the...
8.
Kondo K, Chijiiwa K, Funagayama M, Kai M, Otani K, Ohuchida J
J Gastrointest Surg
. 2007 Nov;
12(3):468-76.
PMID: 17999119
Long-term postoperative survival and prognostic factors were examined retrospectively in patients with hepatocellular carcinoma (HCC) with serum hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCVAb) and in those...